← All trials
NCT03651089
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 16, 2018
- Primary completion
- Dec 31, 2018
- Completion date
- Aug 1, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 24
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Serpin Pharma, LLCLead sponsor
- Virginia Commonwealth UniversityOverall official - principal investigator
- Virginia Commonwealth UniversityCollaborator
- George Mason UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.